Review

anti igfbp5 (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems anti igfbp5
Anti Igfbp5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+igfbp5/Mouse+IGFBP-5+Antibody/pmc13111640-229-54-56
Average 93 stars, based on 19 article reviews

anti igfbp5 - by Bioz Stars, 2026-09

93/100 stars

Images

Blocking Assay:

Article Title: Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity
Article Snippet: .. The slides were washed again with PBS, blocked for 2 h at room temperature with SerumFree Protein Block (Dako, Cat# X0909), probed at 4°C overnight with the primary antibodies at 1/1000 dilution (anti-SRF, Cell signaling Tech, Cat# D71A9; anti-IGFBP5, R&D systems, Cat# AF875; antiMRTFA, Abcam, Cat# ab49311), stained for 30 min with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Dako, Cat# K4003) or Goat-IgG VECTASTAIN ABC-HRP Kit (Vector Cat# PK-4005), and developed with Liquid DAB+ Substrate Chromogen System (Dako, Cat# K3468). .. Finally, the specimens were counterstained with Mayer’s hematoxylin (Dako, Cat# S3309) and mounted with Shandon Synthetic Mount (Thermo Cat# 6769007).

Article Title: Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity
Article Snippet: .. The slides were washed again with PBS, blocked for 2 h at room temperature with Serum- Free Protein Block (Dako, Cat# X0909), probed at 4°C overnight with the primary antibodies at 1/1000 dilution (anti-SRF, Cell signaling Tech, Cat# D71A9; anti-IGFBP5, R&D systems, Cat# AF875; anti- MRTFA, Abcam, Cat# ab49311), stained for 30 min with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Dako, Cat# K4003) or Goat-IgG VECTASTAIN ABC-HRP Kit (Vector Cat# PK-4005), and developed with Liquid DAB+ Substrate Chromogen System (Dako, Cat# K3468). .. Finally, the specimens were counterstained with Mayer’s hematoxylin (Dako, Cat# S3309) and mounted with Shandon Synthetic Mount (Thermo Cat# 6769007).

Staining:

Article Title: Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice
Article Snippet: The slides were stained with 0.1% Sirius Red in saturated picric acid (26357-02, Electron Microscopy Sciences) and visualized under polarized light using our previously described method. .. To investigate the expression of specific proteins, immunohistochemistry staining was performed as described previously using the following primary antibodies: anti-Periostin (19899-1, Proteintech, Wuhan, China), anti-RUNX2 (ab192256, Abcam, Boston, USA), anti-Cathepsin K (ab300569, Abcam), anti-Osterix (ab22552, Abcam), anti-PTH1R (PA5-80955, Invitrogen), anti-Collagen III (22734-1-AP, Proteintech), anti-Decorin (ab277636, Abcam), anti-alkaline phosphatase (ALP, AF2910-SP, R&D Systems, Minneapolis, MN), anti-IGFBP5 (AF578, R&D Systems), anti-Netrin-4 (AF1132, R&D Systems), anti-Nfib (NBP3-32647, Novus Biologicals, Littleton, CO), anti-Jagged-1 (NB600-1161, Novus Biologicals), anti-S100A4 (810101, BioLegend, San Diego, CA), anti-CD73 (A25914, ABclonal Technology, Woburn, MA), anti-PTHrP (A3183, ABclonal Technology), and anti-Osteocalcin (M173, Takara Bio Inc, Otsu, Japan). .. For fluorescence detection, goat anti-rabbit IgG (H + L) cross-adsorbed antibody (A21244, Invitrogen, Carlsbad, CA) was used.

Article Title: Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity
Article Snippet: .. The slides were washed again with PBS, blocked for 2 h at room temperature with Serum- Free Protein Block (Dako, Cat# X0909), probed at 4°C overnight with the primary antibodies at 1/1000 dilution (anti-SRF, Cell signaling Tech, Cat# D71A9; anti-IGFBP5, R&D systems, Cat# AF875; anti- MRTFA, Abcam, Cat# ab49311), stained for 30 min with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Dako, Cat# K4003) or Goat-IgG VECTASTAIN ABC-HRP Kit (Vector Cat# PK-4005), and developed with Liquid DAB+ Substrate Chromogen System (Dako, Cat# K3468). .. Finally, the specimens were counterstained with Mayer’s hematoxylin (Dako, Cat# S3309) and mounted with Shandon Synthetic Mount (Thermo Cat# 6769007).

Expressing:

Immunohistochemistry:

Image Search Results

A Volcano plot of DEGs in ligament cells following ADAM12 knockdown. B Representative enriched pathways from GO, KEGG, and REACTOME analysis of genes altered by ADAM12 knockdown. C Correlation analysis between ADAM12 expression and glycolysis pathway activity from transcriptomic data. D , E Western blot analysis of IGFBP5 and cleaved IGFBP5 protein levels after ADAM12 knockdown and overexpression. n = 3. F , G Western blot analysis of total and phosphorylated levels of IGF1R, PI3K, AKT, and mTOR proteins after ADAM12 knockdown and overexpression. n = 3. H , I IGF1 concentration in cell culture supernatant measured by ELISA after ADAM12 knockdown and overexpression. n = 5. J Western blot analysis of glycolytic enzymes (HK2, LDHA) and osteogenic markers (RUNX2, ALP) in ADAM12-overexpressing cells treated with Linsitinib or Rapamycin. n = 3. K , L Glucose uptake and lactate production in ADAM12-overexpressing cells treated with Linsitinib or Rapamycin. n = 3. M ECAR measurements in ADAM12-overexpressing cells treated with Linsitinib or Rapamycin. n = 3. Data are presented as mean ± standard deviation.

Journal: Cell Death Discovery

Article Title: Glycolytic reprogramming mediated by the ADAM12/IGF1 axis promotes ossification of the posterior longitudinal ligament

doi: 10.1038/s41420-026-03044-8

Figure Lengend Snippet: A Volcano plot of DEGs in ligament cells following ADAM12 knockdown. B Representative enriched pathways from GO, KEGG, and REACTOME analysis of genes altered by ADAM12 knockdown. C Correlation analysis between ADAM12 expression and glycolysis pathway activity from transcriptomic data. D , E Western blot analysis of IGFBP5 and cleaved IGFBP5 protein levels after ADAM12 knockdown and overexpression. n = 3. F , G Western blot analysis of total and phosphorylated levels of IGF1R, PI3K, AKT, and mTOR proteins after ADAM12 knockdown and overexpression. n = 3. H , I IGF1 concentration in cell culture supernatant measured by ELISA after ADAM12 knockdown and overexpression. n = 5. J Western blot analysis of glycolytic enzymes (HK2, LDHA) and osteogenic markers (RUNX2, ALP) in ADAM12-overexpressing cells treated with Linsitinib or Rapamycin. n = 3. K , L Glucose uptake and lactate production in ADAM12-overexpressing cells treated with Linsitinib or Rapamycin. n = 3. M ECAR measurements in ADAM12-overexpressing cells treated with Linsitinib or Rapamycin. n = 3. Data are presented as mean ± standard deviation.

Article Snippet: Primary antibodies used were as follows: ADAM12 (Proteintech, 14139-1-AP), RUNX2 (Abclonal, A11753), OSX (Abclonal, A18699), ALP (Zenbio, 381009), HK2 (Zenbio, R24552 ), PKM2 (Zenbio, R381318), GLUT1 (Zenbio, R380464), PDK1 (Zenbio, R381931), LDHA (Zenbio, R22873 ), cytochrome c (Zenbio, R22867 ), ATP5A (Zenbio, R381760), PGC1α (Zenbio, R381615), mtTFA (Zenbio, R22594 ), IGFBP5 (Proteintech, 55205-1-AP), IGFBP3 (Proteintech, 10189-2-AP), IGF1R (Zenbio, R26882 ), phosphorylated IGF1R (Zenbio, R24720 ), PI3K (Zenbio, R25368 ), phosphorylated PI3K (Zenbio, 341468), AKT (Zenbio, 342529), phosphorylated AKT (Zenbio, 310021), mTOR (Zenbio, R380411), phosphorylated mTOR (Zenbio, R25033 ), and β-actin (Zenbio, R380624).

Techniques: Knockdown, Expressing, Activity Assay, Western Blot, Over Expression, Concentration Assay, Cell Culture, Enzyme-linked Immunosorbent Assay, Standard Deviation

a) Dot plot representing IGFBP5 (left), IGFBP6 (centre) and IGFBP7 (right) expressions in different cell types in publicly available lung single-cell RNA sequencing datasets. Data was generated from the Curated Cancer Cell Atlas. The size of the circle dot represents the percentage of expressing cells, while the colour represents the mean log2 expression level, as indicated in the scale bar (below), b) mRNA expression (fold change) of IGFBP5, 6 and 7 in patient-derived lung normal fibroblasts (NF) and cancer-associated fibroblasts (CAF). Data are presented as mean ± SEM (n=3 biological triplicates). Statistical analysis was conducted using an unpaired t-test with Welch’s correction; exact p-values are represented in the graph, c) Immunoblots (IBs) showing IGFBP5, 6 and 7 expressions in whole cell lysates of NF and CAF. β-Actin served as the loading control. Densitometric analysis was done using Image Lab (v6.1.0), d) IBs showing secreted and cellular (corresponding serum-starved cell lysates) expression of IGFBP5, 6 and 7. β-Actin served as the loading control for serum-starved cellular lysates, while Ponceau blot served as the loading control for secretory lysates. All IBs are representative of three biological triplicates.

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Dot plot representing IGFBP5 (left), IGFBP6 (centre) and IGFBP7 (right) expressions in different cell types in publicly available lung single-cell RNA sequencing datasets. Data was generated from the Curated Cancer Cell Atlas. The size of the circle dot represents the percentage of expressing cells, while the colour represents the mean log2 expression level, as indicated in the scale bar (below), b) mRNA expression (fold change) of IGFBP5, 6 and 7 in patient-derived lung normal fibroblasts (NF) and cancer-associated fibroblasts (CAF). Data are presented as mean ± SEM (n=3 biological triplicates). Statistical analysis was conducted using an unpaired t-test with Welch’s correction; exact p-values are represented in the graph, c) Immunoblots (IBs) showing IGFBP5, 6 and 7 expressions in whole cell lysates of NF and CAF. β-Actin served as the loading control. Densitometric analysis was done using Image Lab (v6.1.0), d) IBs showing secreted and cellular (corresponding serum-starved cell lysates) expression of IGFBP5, 6 and 7. β-Actin served as the loading control for serum-starved cellular lysates, while Ponceau blot served as the loading control for secretory lysates. All IBs are representative of three biological triplicates.

Article Snippet: Cells were lysed directly with RIPA buffer or Laemmli buffer and subjected to SDS PAGE and primary antibodies of α-Smooth Muscle Actin (#19245, CST, 1:1000), FAP (#66562, CST, 1:1000), S100A4 (#13018, CST, 1:1000), IGFBP5 (sc-515184, Santa Cruz, 1:1000), IGFBP6 (AF876, R&D Systems, 1:1000), IGFBP7(sc-365293, Santa Cruz 1:750), Phospho-p44/42 MAPK (Thr202/Tyr204) (#9101, CST, 1:2000), p44/42 MAPK (Thr202/Tyr204) (137F5)(#4695, CST, 1:2000), Phospho-Akt (Ser473) (#4060, CST, 1:2000), Akt (pan) (#2920, CST, 1:2000), Phospho-Insulin R(Y1162/Y1163)/IGF-1R (Y1132/Y1136) (AF2507, R&D Systems, 1:1000), IGF-I R/IGF1R (MAB391, R&D Systems, 1:1000), Phospho-Stat3 (Tyr705) (#9145, CST, 1:2000), Stat3 (#9139, CST, 1:2000), IL6 (#12153, CST, 1:1000), β-Actin (8H10D10) (#3700, CST, 1:2000), GAPDH (#2118, CST, 1:10,000).

Techniques: RNA Sequencing, Generated, Expressing, Derivative Assay, Western Blot, Control

a) Schematics showing investigation of IGFBP5, 6 and 7 roles in CAF biology through transient and stable knockdown approaches. Illustration was prepared using Biorender.com, b) Immunoblots showing knockdown validation of IGFBP5, 6 and 7 in CAF upon transient transfection. GAPDH and β-Actin served as the loading control. The IBs represent three biological replicates, c) Representative immunofluorescence images showing F-actin staining (red) and DAPI (blue) in CAF upon individual and pooled knockdown of IGFBPs, scale bar 45μm, d) Quantification of cell area for (c). Quantification was performed for a minimum of thirty cells, which were included from three biological replicates. Data are presented as mean ± SEM, with open circles indicating individual cells. Statistical analysis was conducted using the Kruskal-Wallis test with Dunn’s multiple comparison; exact p-values are indicated in the graph, e) Schematics showing collagen contraction experiment. Illustration was prepared using Biorender.com, f) Image representing technical duplicates of collagen contraction upon individual and pooled knockdown of IGFBP5, 6 and 7. Yellow dotted lines mark the boundary of the gel, g) Quantification of the area of the gel disk is represented as a bar plot with mean ± SEM, n=4 biological replicates, h) Representative brightfield images of migrated cells (crystal violet stained) after IGFBP5, 6 and 7 knockdowns, scale bar 200μm. Images were captured 16 hours after wiping off the non-migrated cells in the upper chamber, i) Cell count of the migrated cells is taken as an average of four different fields of one experiment. Data represent mean (relative cell count with respect to control (%) ± SEM, n= 3 biological replicates, (g, i) To determine statistical significance, One-way ANOVA with Dunnett’s multiple comparison was used; exact p-values are indicated in the graph.

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Schematics showing investigation of IGFBP5, 6 and 7 roles in CAF biology through transient and stable knockdown approaches. Illustration was prepared using Biorender.com, b) Immunoblots showing knockdown validation of IGFBP5, 6 and 7 in CAF upon transient transfection. GAPDH and β-Actin served as the loading control. The IBs represent three biological replicates, c) Representative immunofluorescence images showing F-actin staining (red) and DAPI (blue) in CAF upon individual and pooled knockdown of IGFBPs, scale bar 45μm, d) Quantification of cell area for (c). Quantification was performed for a minimum of thirty cells, which were included from three biological replicates. Data are presented as mean ± SEM, with open circles indicating individual cells. Statistical analysis was conducted using the Kruskal-Wallis test with Dunn’s multiple comparison; exact p-values are indicated in the graph, e) Schematics showing collagen contraction experiment. Illustration was prepared using Biorender.com, f) Image representing technical duplicates of collagen contraction upon individual and pooled knockdown of IGFBP5, 6 and 7. Yellow dotted lines mark the boundary of the gel, g) Quantification of the area of the gel disk is represented as a bar plot with mean ± SEM, n=4 biological replicates, h) Representative brightfield images of migrated cells (crystal violet stained) after IGFBP5, 6 and 7 knockdowns, scale bar 200μm. Images were captured 16 hours after wiping off the non-migrated cells in the upper chamber, i) Cell count of the migrated cells is taken as an average of four different fields of one experiment. Data represent mean (relative cell count with respect to control (%) ± SEM, n= 3 biological replicates, (g, i) To determine statistical significance, One-way ANOVA with Dunnett’s multiple comparison was used; exact p-values are indicated in the graph.

Techniques: Knockdown, Western Blot, Biomarker Discovery, Transfection, Control, Immunofluorescence, Staining, Comparison, Cell Counting

a) Volcano plot representing differentially expressed genes between CAF siControl vs siIGFBP5 b) CAF siControl vs siIGFBP6 c) CAF siControl vs siIGFBP7 (n=3 biological replicates). A log2 fold change of 0.5 was set as the threshold. Selected genes for validation are marked in blue. d) Enriched pathways based on the differentially expressed genes upon IGFBP5 knockdown e) IGFBP6 knockdown f) IGFBP7 knockdown g) Heatmap comparing the published CAF subtype gene sets with CAF siControl versus siIGFBP5 h) CAF siControl versus siIGFBP6 i) CAF siControl versus siIGFBP7 (n=2 biological replicates)

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Volcano plot representing differentially expressed genes between CAF siControl vs siIGFBP5 b) CAF siControl vs siIGFBP6 c) CAF siControl vs siIGFBP7 (n=3 biological replicates). A log2 fold change of 0.5 was set as the threshold. Selected genes for validation are marked in blue. d) Enriched pathways based on the differentially expressed genes upon IGFBP5 knockdown e) IGFBP6 knockdown f) IGFBP7 knockdown g) Heatmap comparing the published CAF subtype gene sets with CAF siControl versus siIGFBP5 h) CAF siControl versus siIGFBP6 i) CAF siControl versus siIGFBP7 (n=2 biological replicates)

Techniques: Biomarker Discovery, Knockdown

a) Ligand activity analysis showing the list of potential ligands that can regulate differentially expressed genes upon IGFBP5 knockdown in CAF, d) IGFBP6 knockdown, g) IGFBP7 knockdown, b) Ligand-target matrix showing the regulatory potential of potential ligands with CAF siControl vs siIGFBP5, e) CAF siControl vs siIGFBP6, h) CAF siControl vs siIGFBP7, c) Western blot analysis of CAF siControl and siIGFBP5, f) CAF siControl and siIGFBP6, i) CAF siControl and siIGFBP7, after treatment with TGFβ1[10 ng/mL] and IL6 [10 ng/mL] for 48 hours. Densitometric analysis was done using Image Lab (v6.1.0). All IBs are representative of three biological triplicates.

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Ligand activity analysis showing the list of potential ligands that can regulate differentially expressed genes upon IGFBP5 knockdown in CAF, d) IGFBP6 knockdown, g) IGFBP7 knockdown, b) Ligand-target matrix showing the regulatory potential of potential ligands with CAF siControl vs siIGFBP5, e) CAF siControl vs siIGFBP6, h) CAF siControl vs siIGFBP7, c) Western blot analysis of CAF siControl and siIGFBP5, f) CAF siControl and siIGFBP6, i) CAF siControl and siIGFBP7, after treatment with TGFβ1[10 ng/mL] and IL6 [10 ng/mL] for 48 hours. Densitometric analysis was done using Image Lab (v6.1.0). All IBs are representative of three biological triplicates.

Techniques: Activity Assay, Knockdown, Western Blot

a) H460 cells (masked-yellow) treated with conditioned media (CM) derived from CAF individual and pooled knockdowns of IGFBP5, 6 and 7, image shown here is a representative for the 72-hour timepoint, b) Graph represents mean ± SEM showing the proliferation of tumour cells represented as confluence percentage over a 72-hour time interval, the line colour represents different conditions, n=3, * indicates p-value less than 0.05, c) Representative brightfield images of invaded cells (crystal violet stained) of tumour cells towards conditioned media derived from individual and pooled IGFBP5, 6 and 7 knockdowns in CAF, scale bar 200μm. Images were captured 16 hours after wiping off the non-invaded cells in the upper chamber. d) Cell count of the invaded cells is taken as an average of four different fields of one experiment. Data represent mean ± SEM, n=3 biological replicates. To determine statistical significance, Oneway ANOVA with Dunnett’s multiple comparison was used; exact p-values are indicated in the graph, e) H460 cells (masked- yellow) treated with the IC 50 values of cisplatin [4.8 μM] with CM derived from CAF individual and pooled knockdowns of IGFBP5, 6 and 7, image shown here is a representative for the 72-hour time-point, f) Graph represents mean ± SEM showing the tumour cells represented as confluence percentage over a 72-hour time interval, the line colour represents different conditions, n=3, * indicates p-value less than 0.05, **** indicates pvalue less than 0.0001. g) Schematics showing in-vivo experiment design, illustration was prepared using Biorender.com. h) m-Cherry expressing H460 tumour cells were injected subcutaneously alone (0.5 * 10 6 cells) or co-injected with GFP-expressing CAF individual IGFBP5, 6 or 7 knockdown or shControl (1.5 * 10 6 cells) in male NOD-SCID mice. Tumours were excised on the 16 th day. i) Tumour volume and j) tumour weight were measured after the tumours were excised; data are represented for 6 mice from three independent experiments. Dunnet’s multiple comparison test was used to determine statistical significance.

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) H460 cells (masked-yellow) treated with conditioned media (CM) derived from CAF individual and pooled knockdowns of IGFBP5, 6 and 7, image shown here is a representative for the 72-hour timepoint, b) Graph represents mean ± SEM showing the proliferation of tumour cells represented as confluence percentage over a 72-hour time interval, the line colour represents different conditions, n=3, * indicates p-value less than 0.05, c) Representative brightfield images of invaded cells (crystal violet stained) of tumour cells towards conditioned media derived from individual and pooled IGFBP5, 6 and 7 knockdowns in CAF, scale bar 200μm. Images were captured 16 hours after wiping off the non-invaded cells in the upper chamber. d) Cell count of the invaded cells is taken as an average of four different fields of one experiment. Data represent mean ± SEM, n=3 biological replicates. To determine statistical significance, Oneway ANOVA with Dunnett’s multiple comparison was used; exact p-values are indicated in the graph, e) H460 cells (masked- yellow) treated with the IC 50 values of cisplatin [4.8 μM] with CM derived from CAF individual and pooled knockdowns of IGFBP5, 6 and 7, image shown here is a representative for the 72-hour time-point, f) Graph represents mean ± SEM showing the tumour cells represented as confluence percentage over a 72-hour time interval, the line colour represents different conditions, n=3, * indicates p-value less than 0.05, **** indicates pvalue less than 0.0001. g) Schematics showing in-vivo experiment design, illustration was prepared using Biorender.com. h) m-Cherry expressing H460 tumour cells were injected subcutaneously alone (0.5 * 10 6 cells) or co-injected with GFP-expressing CAF individual IGFBP5, 6 or 7 knockdown or shControl (1.5 * 10 6 cells) in male NOD-SCID mice. Tumours were excised on the 16 th day. i) Tumour volume and j) tumour weight were measured after the tumours were excised; data are represented for 6 mice from three independent experiments. Dunnet’s multiple comparison test was used to determine statistical significance.

Techniques: Derivative Assay, Staining, Cell Counting, Comparison, In Vivo, Expressing, Injection, Knockdown

a) Formalin-fixed paraffin-embedded NSCLC tumour sections were stained with hematoxylin and eosin, Sirius Red, antibodies against α-SMA, IGFBP5, 6 and 7. Cases 1 and 2 represent two different patients. ‘T’ indicates tumour and ‘S’ indicates stroma. The arrow indicates the expression of the respective proteins in fibroblasts; scale bar, 50 μm. b) Representative multiplex immunofluorescence staining images of IGFBP5+, IGFBP6+ and IGFBP7+ CAFs. DAPI (blue), αSMA (green), FAP (pink), PanCK (red), IGFBP5 (grey), IGFBP6 (yellow), IGFBP7 (orange) in human non-small-cell lung cancer tissue sections. Scale bars 50 μm. c) survival between high and low expression of CAF_IGFBP5 gene signatures d) CAF_IGFBP6 gene signatures e) CAF_IGFBP7 gene signatures in TCGA-LUAD datasets, pvalues were obtained from two-sided log-Rank tests.

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Formalin-fixed paraffin-embedded NSCLC tumour sections were stained with hematoxylin and eosin, Sirius Red, antibodies against α-SMA, IGFBP5, 6 and 7. Cases 1 and 2 represent two different patients. ‘T’ indicates tumour and ‘S’ indicates stroma. The arrow indicates the expression of the respective proteins in fibroblasts; scale bar, 50 μm. b) Representative multiplex immunofluorescence staining images of IGFBP5+, IGFBP6+ and IGFBP7+ CAFs. DAPI (blue), αSMA (green), FAP (pink), PanCK (red), IGFBP5 (grey), IGFBP6 (yellow), IGFBP7 (orange) in human non-small-cell lung cancer tissue sections. Scale bars 50 μm. c) survival between high and low expression of CAF_IGFBP5 gene signatures d) CAF_IGFBP6 gene signatures e) CAF_IGFBP7 gene signatures in TCGA-LUAD datasets, pvalues were obtained from two-sided log-Rank tests.

Techniques: Formalin-fixed Paraffin-Embedded, Staining, Expressing, Multiplex Assay, Immunofluorescence

Tumour cells secrete TGFβ1 and IL6, which regulate IGFBP5, 6 and 7 expressions in cancer-associated fibroblasts. These high IGFBP-expressing CAFs show pro-tumorigenic effects and are associated with poor patient outcomes. On the other hand, knocking down IGFBP5, 6, and 7 selectively pushes CAF towards distinct subtypes, which suppresses tumour properties and correlates with better survival.

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: Tumour cells secrete TGFβ1 and IL6, which regulate IGFBP5, 6 and 7 expressions in cancer-associated fibroblasts. These high IGFBP-expressing CAFs show pro-tumorigenic effects and are associated with poor patient outcomes. On the other hand, knocking down IGFBP5, 6, and 7 selectively pushes CAF towards distinct subtypes, which suppresses tumour properties and correlates with better survival.

Techniques: Expressing

Review

anti igfbp5 (R&D Systems)

Structured Review

Images

Related Articles

Blocking Assay:

Staining:

Expressing:

Immunohistochemistry:

Similar Products

Image Search Results